Apex Drugs Limited, a active public limited company, was established on 05 December 1989 in Jinnaram, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24230TG1989PLC010737. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹25.00 Cr and a paid-up capital of ₹2.00 Cr.
Formerly known as Apex Drugs And Intermediates Limited. It upholds a compliant status. Employing 31 professional, Its leadership includes Gajanana Kudva (Director), Kajal Kiran Damania (Director), Shankar Sitaram Dige (Cfo). Past directors included Vilas Ramkrishna Lokhande, Ghanshyam Surajbali Kurmi, Kunal Nand Rohra. It holds no open charges and ₹135.21 Cr settled loans. Its latest AGM occurred on 30 September 2022, with the balance sheet filed on 31 March 2022. It is based at Survey No.14 Gaddapotharam, Jinnaram, Telangana, 502319.
U24230TG1989PLC010737
010737
05 December 1989
₹25.00 Cr
₹2.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Apex Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gajanana Kudva | Director | 29 Aug 2020 | Current |
| Kajal Kiran Damania | Director | 28 Aug 2020 | Current |
| Shankar Sitaram Dige | Cfo | 15 Sep 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Whole-Time Director | 05 Feb 2015 | Past |
| Pramod Abcsdd | Whole-Time Director | 01 Jun 2011 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Director | 14 Jan 2021 | Past |
| Pramod Abcsdd | Additional Director | 11 Jul 2019 | Past |
| Pramod Abcsdd | Additional Director | 01 Mar 2010 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Apex Drugs Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 101.5%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
In 2022, Apex Drugs had a promoter holding of 99.94% and a public holding of 0.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹1,352,114,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Dec 2010 | Allahabad Bank | ₹16.00 Cr | Satisfied |
| 12 Sep 2008 | Bank Of India | ₹23.85 Cr | Satisfied |
| 23 Apr 2007 | Icici Bank Limited | ₹22.20 Cr | Satisfied |
| 24 Feb 2003 | State Bank Of India | ₹3.50 Cr | Satisfied |
| 24 Feb 2003 | State Bank Of India | ₹66.54 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Apex Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Apex Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apex Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Apex Drugs Limited last Annual general meeting of members was held on 30 Sep 2022 as per latest MCA records. was documented.
Progress on Apex Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Hyderabad. was documented.
A charge registered on 01 Dec 2010 via Charge ID 10254676 with Allahabad Bank was fully satisfied on 15 Sep 2021. was recorded as a recent event.
A charge registered on 12 Sep 2008 via Charge ID 10124609 with Bank Of India was fully satisfied on 15 Sep 2021. was recorded as a recent event.
Progress on Shankar Sitaram Dige was appointed as a CFO was appointed as a CFO on 15 Sep 2021 & has been associated with this company since 4 years 4 months . was documented.
Shankar Sitaram Dige was appointed as a CFO was appointed as a CFO on 15 Sep 2021 & has been associated with this company since 4 years 4 months . was recorded as a recent event.
The CIN of Apex Drugs Limited is U24230TG1989PLC010737.
Apex Drugs Limited is headquartered at Survey No.14 Gaddapotharam, Jinnaram, Telangana, 502319.
Apex Drugs Limited was incorporated on 05 December 1989.
The current directors of Apex Drugs Limited are
The primary industry of Apex Drugs Limited is Manufacturing.
Apex Drugs Limited is unlisted.
The authorized capital of Apex Drugs Limited is ₹25.00 Cr, and the paid-up capital is ₹2.00 Cr.
The compliance status of Apex Drugs Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX